158 related articles for article (PubMed ID: 21075440)
1. A new index of priority symptoms in advanced ovarian cancer.
Jensen SE; Rosenbloom SK; Beaumont JL; Abernethy A; Jacobsen PB; Syrjala K; Cella D
Gynecol Oncol; 2011 Feb; 120(2):214-9. PubMed ID: 21075440
[TBL] [Abstract][Full Text] [Related]
2. Content validity of the NCCN-FACT ovarian symptom index-18 (NFOSI-18).
Jensen SE; Kaiser K; Lacson L; Schink J; Cella D
Gynecol Oncol; 2015 Feb; 136(2):317-22. PubMed ID: 25499602
[TBL] [Abstract][Full Text] [Related]
3. Reliability, validity and important difference estimates for the NCCN-FACT Ovarian Symptom Index-18 (NFOSI-18).
Trigg A; Kelly M; Iadeluca L; Chang J; Moreno-Koehler A; Yaworsky A; Krohe M; Rider A; Cappelleri JC; Cella D; Cocks K
Future Oncol; 2021 Oct; 17(30):3951-3964. PubMed ID: 34287020
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of Ovarian Symptom Index-18 and Neurotoxicity-4 for Korean Patients with Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
Lee M; Lee Y; Kim K; Park EY; Lim MC; Kim JS; Kim HS; Kim YB; Kim YM; Joo J; Park SY; Choi CH; Kim JH
Cancer Res Treat; 2019 Jan; 51(1):112-118. PubMed ID: 29510610
[TBL] [Abstract][Full Text] [Related]
5. Measuring priority symptoms in advanced bladder cancer: development and initial validation of a brief symptom index.
Jensen SE; Beaumont JL; Jacobsen PB; Abernethy A; Syrjala KL; Cella D
J Support Oncol; 2013 Jun; 11(2):86-93. PubMed ID: 23089235
[TBL] [Abstract][Full Text] [Related]
6. Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials.
Shaunfield S; Jensen S; Fisher AP; Webster K; Shahabi S; Ganguli A; Cella D
Health Qual Life Outcomes; 2019 Dec; 17(1):185. PubMed ID: 31856850
[TBL] [Abstract][Full Text] [Related]
7. Development and initial validation of the NCCN/FACT symptom index for advanced kidney cancer.
Rothrock NE; Jensen SE; Beaumont JL; Abernethy AP; Jacobsen PB; Syrjala K; Cella D
Value Health; 2013; 16(5):789-96. PubMed ID: 23947972
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcome changes at the end of life in recurrent platinum-resistant ovarian cancer: An NRG oncology/GOG study.
Wenzel L; Huang HQ; Cella D; McKinney CO; Zevon MA; LaChance JA; Walker JL; Salani R; Modesitt SC; Morris RT; Bradley WH; Boente MP; von Gruenigen VE
Gynecol Oncol; 2021 Nov; 163(2):392-397. PubMed ID: 34548162
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of treatment- and disease-related symptoms in advanced head and neck cancer: validation of the national comprehensive cancer network-functional assessment of cancer therapy-head and neck cancer symptom index-22 (NFHNSI-22).
Pearman TP; Beaumont JL; Paul D; Abernethy AP; Jacobsen PB; Syrjala KL; Von Roenn J; Cella D
J Pain Symptom Manage; 2013 Jul; 46(1):113-20. PubMed ID: 23017622
[TBL] [Abstract][Full Text] [Related]
10. Development of the measure of ovarian symptoms and treatment concerns: aiming for optimal measurement of patient-reported symptom benefit with chemotherapy for symptomatic ovarian cancer.
King MT; Stockler MR; Butow P; O'Connell R; Voysey M; Oza AM; Gillies K; Donovan HS; Mercieca-Bebber R; Martyn J; Sjoquist K; Friedlander ML
Int J Gynecol Cancer; 2014 Jun; 24(5):865-73. PubMed ID: 24844220
[TBL] [Abstract][Full Text] [Related]
11. Reliability and validity of the functional assessment of cancer therapy-ovarian.
Basen-Engquist K; Bodurka-Bevers D; Fitzgerald MA; Webster K; Cella D; Hu S; Gershenson DM
J Clin Oncol; 2001 Mar; 19(6):1809-17. PubMed ID: 11251013
[TBL] [Abstract][Full Text] [Related]
12. Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.
King MT; Stockler MR; O'Connell RL; Buizen L; Joly F; Lanceley A; Hilpert F; Okamoto A; Aotani E; Bryce J; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Sehouli J; Feeney A; Berton-Rigaud D; Costa DSJ; Friedlander ML;
Qual Life Res; 2018 Jan; 27(1):59-74. PubMed ID: 29248998
[TBL] [Abstract][Full Text] [Related]
13. A preliminary study of a health related quality of life assessment of priority symptoms in advanced lymphoma: the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy - Lymphoma Symptom Index.
Hlubocky FJ; Webster K; Beaumont J; Cashy J; Paul D; Abernethy A; Syrjala KL; Von Roenn J; Cella D
Leuk Lymphoma; 2013 Sep; 54(9):1942-6. PubMed ID: 23320888
[TBL] [Abstract][Full Text] [Related]
14. A brief symptom index for advanced lung cancer.
Yount S; Beaumont J; Rosenbloom S; Cella D; Patel J; Hensing T; Jacobsen PB; Syrjala K; Abernethy AP
Clin Lung Cancer; 2012 Jan; 13(1):14-23. PubMed ID: 21729652
[TBL] [Abstract][Full Text] [Related]
15. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
von Gruenigen VE; Huang HQ; Cella D; Zevon M; LaChance JA; Walker JL; Salani R; Modesitt SC; Morris RT; Bradley WH; Boente MP; Wenzel L
Gynecol Oncol; 2018 Jul; 150(1):119-126. PubMed ID: 29778506
[TBL] [Abstract][Full Text] [Related]
16. Development of a symptom index for patients with primary brain tumors.
Lai JS; Jensen SE; Beaumont JL; Abernethy AP; Jacobsen PB; Syrjala K; Raizer JJ; Cella D
Value Health; 2014; 17(1):62-9. PubMed ID: 24438718
[TBL] [Abstract][Full Text] [Related]
17. Priority symptoms in advanced breast cancer: development and initial validation of the National Comprehensive Cancer Network-Functional Assessment of Cancer Therapy-Breast Cancer Symptom Index (NFBSI-16).
Garcia SF; Rosenbloom SK; Beaumont JL; Merkel D; Von Roenn JH; Rao D; Cella D
Value Health; 2012 Jan; 15(1):183-90. PubMed ID: 22264987
[TBL] [Abstract][Full Text] [Related]
18. Effect of cancer stage on health-related quality of life of patients with epithelial ovarian cancer.
Techata A; Muangmool T; Wongpakaran N; Charoenkwan K
J Obstet Gynaecol; 2022 Jan; 42(1):139-145. PubMed ID: 33938358
[TBL] [Abstract][Full Text] [Related]
19. Development of an ovarian cancer symptom index: possibilities for earlier detection.
Goff BA; Mandel LS; Drescher CW; Urban N; Gough S; Schurman KM; Patras J; Mahony BS; Andersen MR
Cancer; 2007 Jan; 109(2):221-7. PubMed ID: 17154394
[TBL] [Abstract][Full Text] [Related]
20. The reliability, validity, and preliminary responsiveness of the Eye Allergy Patient Impact Questionnaire (EAPIQ).
Alexander M; Berger W; Buchholz P; Walt J; Burk C; Lee J; Arbuckle R; Abetz L
Health Qual Life Outcomes; 2005 Oct; 3():67. PubMed ID: 16259630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
